natgillin/translations-raw huggingface dataset:
The first antigen binding protein according to claim 1 that competes for binding to the extracellular portion of human c-fms with a second antigen binding protein, wherein said second antigen binding protein is an antibody comprising complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, wherein said CDRs comprise the amino acid sequences as set forth below: 
Protutijelo, naznačeno time što se bira iz skupine koju čine protutijelo koje sadrži područja za određivanje komplementarnosti (CDR) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, te CDRL3, gdje navedeni CDR-i imaju aminokiselinske sljedove kao što su iznijeti niže:
UV monitor (optical path length 2.5 mm) equipped with two channel recorder (Amersham Biosciences or equivalent); 
- < UV monitor (duljina optičke putanje 2.5 mm) opremljen s dvo kanalnim snimačem (Amersham Biosciences ili njegov ekvivalent);
Rigid groups can include, for example, those groups whose conformational freedom is restrained by the presence of rings and/or bonds, for example, aryl, heteroaryl and heterocyclic groups. 
Krute grupe mogu uključivati, na primjer, grupe čija je konformacijska sloboda ograničena prisutnošću prstena i/ili veza, na primjer, arilne, heteroarilne i heterocikličke grupe.
Cytochrome P450 Inhibition of the Metabolism of Compound 25 
Broj objave europskog patenta:
General methods of organic synthesis and functional group transformations are found in: Trost, B. M. and Fleming, I., eds. 
Opći postupci organske sinteze i transformacija funkcionalne skupine pronađeni su u: Trost, B.M.
The heating program was started. 
Pokrenut je program zagrijavanja.
The floating lake system of claim 11, wherein the flexible materials of the frame components comprise rubber, plastic, fabric, nylon, or combinations thereof. 
Sustav plutajućeg jezera (1) prema zahtjevu 24, naznačen time što savitljivi materijali komponenti okvira sadrže gumu, plastiku, tkaninu, najlon ili njihove kombinacije.
One method of separating pairs of enantiomers obtained from each of Processes A and B, and which has been found to be particularly effective, is to esterify the hydroxyl group of the dihydrotetrabenazine with an optically active form of Mosher's acid, such as the R (+) isomer shown below, or an active form thereof: 
Jedan postupak odijeljivanja parova enantiomera dobivenih svakim od postupaka A 1B, koji se pokazao kao posebno učinkovit, je esterifikacija hidroksi skupine dihidrotetrabenazina s optički aktivnim oblikom Mosher-ove kiseline, poput R (+) izomera prikazanog dolje ili njegovog aktivnog oblika: HR P20090074 T3
The amount of protein in the eluted fraction was analyzed by ELISA and/or by SDS-PAGE. 
Količina proteine u eluiranoj frakciji analizirana je testovima ELISA i/ili SDS-PAGE.
A line broadening of 100 Hz was applied to the spectrum before FT was performed. 
Linijsko proširenje od 100 Hz je primjenjeno na spektar prije nego je FT rađen.
The method of claim 1, wherein the cancer is non-small cell lung cancer, small cell lung cancer, bladder cancer, upper gastrointestinal cancer, gastric cancer, gallbladder cancer, ovarian cancer, glioblastoma, a sarcoma or a hematological cancer. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se rak bira između raka pluća, raka dojke, raka jetre, raka jajnika, raka želuca, gastrointestinalnog raka, raka žučnog mjehura, raka mokraćnog mjehura, glioblastoma, sarkoma, melanoma, kolorektalnog raka i raka gušterače.
The composition of para 13, wherein the proapoptotic genes are Bak and Bax. 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 10, naznačen time da proapoptotički geni su Bak i Bax.
PCT International Publication No. 
Datum međunarodne objave:
disodium edetate; wherein the disodium edetate is present in an amount of about 0.12 mg/ml; 
(c) dinatrijev odetat; pri čemu so dinatrijev edetat nalazi u količini od oko 0.12 mg/ml;
Collecting water with a concentration of total dissolved solids (TDS) of up to 60,000 ppm, wherein: if the collected water has a total dissolved solids concentration less than or equal to 10,000 ppm, the Langelier Saturation Index must be less than 3, or 
Postupak za obradu vode uz nizak trošak, prema zahtjevu 1, naznačen time što: a. = ako voda prikupljena u stupnju a) ima ukupnu koncentraciju otopljenih krutina manju ili jednaku 10,000 ppm, Langelierov indeks zasićenja mora biti manji od 3; ili b.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
Particularly, the CCBs to be used in the composition of the present invention is selected from the group consisting of amlodipine, verapamil, and diltiazem. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni CCB odabran iz skupine koju čine amlodipin, verapamil i diltiazem.
A conjugated nucleic acid molecule which has the following formula: 
PATENTNI ZAHTJEVI 1. - Konjugirana molekula nukleinske kiseline, naznačena time što ima sljedeću formulu:
an obtaining unit configured for obtaining, from a Picture Parameter Set (PPS) of the current picture in a bitstream, first information indicating whether a dependent slice segment may be used in the current picture; 
dobivanje, iz skupa parametara slike (PPS) trenutne slike u toku bitova, prve informacije koja pokazuje da li se ovisni segment odsječka može koristiti u trenutnoj slici;
Said dosage form comprises a combination of a pharmaceutical extrudate in the form of multiparticulates including 5 mg to 400 mg oxycodone or a salt thereof dispersed in a matrix. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek u obliku davanja koji se daje dvaput dnevno koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u količini od oko 5 mg.
Method according to Claim 13, wherein said provision of said thread reinforcement comprises providing a thread reinforcement web, placing a layer of plastic material on either side of it and fixing said layers of plastic material to each other. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što izvedba navedenog pojačanja od vlakana obuhvaća izradu mrežastog pletenog tkanog materijala od vlakana za pojačanje, stavljanje sloja materijala od plastike na njegove obje strane i pričvršćenje navedenih slojeva materijala od plastike jednog na drugi.
magnetically permeable radially and/or circumferentially extending bridge segments interconnecting the first and second magnetically permeable segments. 
magnetski permeabilne radijalno i/ili obodno proširujuće segmente mosta (56a) koji međusobno povezuju prvi i drugi magnetski permeabilni segment.
A counter as claimed in claim 8, wherein said limiting mechanism (1506) comprises a resiliently deformable portion for applying pressure on said second ring member (202, 1510) for said limiting. 
Brojač kao što je navedeno u zahtjevu 16, naznačeno time da navedeni mehanizam ograničenja (1506) sadrži dio otporan na deformacije za primjenu pritiska na navedeni drugi prstenasti element (202, 1510) za navedeno ograničavanje.
A method for treatment of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, diabetic nephropathy, fibrotic disorders of the heart and dermatological fibroses comprising administering to a human an effective amount of the compound of claim 11 or a salt, a solvate, or a solvate of a salt thereof. 
Spoj kako je definirano u bilo kojem od zahtjeva 1 do 11 naznačen time da je za uporabu u postupku za liječenje i/ili profilaksu zatajenja srca, plućne hipertenzije, kronične opstruktivne plućne bolesti, astme, zatajenja bubrega, nefropatije, fibroznih poremećaja unutarnjih organa i dermatoloških fibroza.
Therefore, the suction cups 8, 9 and gripper 10 can transfer the pouches 102 and spouts 103 to the rotary machine R with precision. 
Na taj način usisne čašice i naprava za hvatanje mogu prenijeti vrećice 102 i kljunove 103 rotacijskom stroju R na vrlo precizan način.
The conjugate of any of claims 1 to 3, wherein said polypeptide is 19 to 50 amino acids in length. 
Konjugat prema zahtjevu 1, naznačen time da je navedeni polipeptid duljine 19 do 50 amino kiselina.
An anti-FcRn antibody or FcRn-binding fragment thereof according to claim 1, which further binds one or more residues selected from the group consisting of L82, Y88, L112 and D130. 
Anti-FcRn antitijelo prema patentnom zahtjevu 7, naznačeno time, što je antitijelo pune dužine odabrano iz skupine koja se sastoji od IgG1, IgG4 i IgG4 S241P.
The beverage production device according to claim 10 or 11, wherein in order to evacuate the at least two thermoblocks (3, 4), valve means (19, 20) are provided to selectively vent air through the hot water outlet (14) and into the thermoblocks (3, 4) for emptying the thermoblocks. 
Naprava za proizvodnju napitaka prema patentnom zahtjevu 10 ili 11, kod koje su, kako bi sc ispraznilo najmanje dva termobloka (3, 4), ugrađeni ventili (19, 20) za selektivno upuhivanje zraka kroz izlaz za vruću vodu (14), te u termoblokove (3, 4) radi pražnjenja termoblokova.
and resolving the resulting diastereomeric mixture via crystallization to provide the compound of formula (II). 
"*" znači kiralni centar s apsolutnom stereokemijom (R) ili (S); te od rastavaranja rezultirajuće dijastereomerne smjese putem kristalizacije, za dobivanje spoja formule (II).
The system of claim 1, wherein the acquired electrical data is processed by the on-board or remote data processing means to produce electrical consumption and/or cost related reports. 
Sustav prema zahtjevu 1, pri čemu instrument na ploči ili udaljeno računalo generiraju izvještaj o potrošnji električni energije i/ili pripadajućim troškovima.
The pharmaceutical composition according to claim 46, further comprising at least one of an anticancer agent, a chemotherapy agent, and an antiproliferative compound. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 46, naznačen time što dodatno sadrži najmanje jedno od sredstva protiv raka, kemoterapijskog sredstva, te antiproliferativnog spoja.
A process according to claim 11, wherein the reaction of the compound of formula (11) with an activated biphenylic compound takes place in the presence of a metal salt additive. 
Postupak prema zahtjevu 33 ili 34, naznačen time, da se reakcija spoja formule (11) s aktiviranim bifenilnim spojem, izvodi u prisutnosti metalne soli kao aditiva.
The capsule according to claim 6, wherein the upper annular edge is made of an elastically deformable plastic material. 
Kapsula u skladu s patentnim zahtjevom 6, naznačena time, da je navedeni gornji prstenasti rub (12) izrađen od savitljivog plastičnog materijala.
The pharmaceutical composition according to claim 1, wherein the cytotoxic activity is an antibody-dependent cell-mediated cytotoxic activity (ADCC activity). 
Farmaceutski pripravak prema zahtjevu 1, naznačen time, što citotoksično djelovanje predstavlja stanično posredovano citotoksično djelovanje ovisno o antitijelu (engl. antibody-dependent cell-mediated; ADCC djelovanje).
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 4,wherein the solid tumor is selected from the group consisting of: lung carcinoma, lung metastasis, and colon carcinoma. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 4, gdje je navedeni solidni tumor odabran iz grupe koja se sastoji od: raka pluća, sarkoma, fibrosarkoma, raka gušterače, raka prostate, i raka debelog crijeva.
In the studies summarized in Tables 1 to 4 each mouse used as EAE model received 200 µl s. c. injection each; the injection contained the active ingredient or the carrier (0.9 % sodium chloride aqueous solution). 
U ispitivanjima koja su sažeta u Tablicama 1 do 4 svaki miš koji je korišten kao EAE model je primio 200 pl s.c. injekciju; injekcija sadrži aktivnu tvar ili nosač (0.9 % vodena otopina natrij klorida).
The compound of formula (I), or a tautomer, mesomer, raceme, enantiomer, diastereomer, and mixture thereof, and a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, or 6, wherein A is N. 
Spoj formule (I), ili njegov tautomer, mezomer, racemat, enantiomer, dijastereomer i smjesa, i njegova farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, naznačeno time što A je N.
In this view, it is important to acknowledge the presence of complex microflora in the gastrointestinal tract (GI tract), more specifically the colon, as being part of healthy human beings. 
S tog je stajališta važno znati da u gastrointestinalnom (GI) sustavu postoji složena mikroflora, napose u debelom crijevu, i da je ona sastavni dio svakog zdravog ljudskog organizma.
In an embodiment the predetermined outer rim joint angle (a) is 75 to 120°, in particular 85 to 110°, in particular 90 to 105°, in particular 98 to 102°. In an embodiment the load bearing frame (61) is “C”-shaped. 
Preša (1) prema prethodnom patentnom zahtjevu pri čemu prethodno određeni spojni kut (a) vanjskog ruba je 75 do 120", naročito 85 do 110", naročito 90 do 105%, naročito 98 do 102".
7,9 acetal linked analogs of 9, 10-aa OH taxanes can also be formed directly from 10-deacetylbaccatin III (10-DAB), which has the formula: 
Alternativni postanak za sintetiziranje 7,9-acetal vezanih analoga 7,9 acetalno vezani analozi 9,10-a,a OH taksana mogu također biti formirani direktno iz 10-deacetilbakatina III (10- DAB), koji ima formulu:
acquiring a proportional signal (90u) proportional to the actual leakage currents and disconnecting the load (16) from the electrical network (10) when reaching a dangerous condition corresponding to an acquired signal of a magnitude greater than a limit value. 
(iv) dobivanjem proporcionalnog signala (90u) koji je proporcionalan pravoj parazitnoj struji i odspajanjem trošila (16) s električne mreže (10) kada se postiže opasno stanje koje odgovara dobivenom signalu većem od granične vrijednosti.
It is even more preferable for the foliar fertilizer in the form of a concentrated foliar fertilizer product to have the following composition: 
Pripravak u obliku vodene suspenzije u skladu s patentnim zahtjevom 5, naznačen time što sadrži:
and treated at that temperature with methylamine (2.0 g., 0.064 mole) and then titanium tetrachloride (dropwise addition, 1.73 g., 0.009 mole). 
i tretira na toj temperaturi sa metilaminom (2.0 g., 0.064 mola) i tada sa titan-tetrakloridom (dodavanje ukapavanje, 1.73 g., 0.009 mola).
The method according to claim 11, wherein the infection is caused by a carbapenemase-resistant strain or “extended spectrum B-lactamase” (ESPL) strain. The method according to claim 1 or claim 7, for the treatment of a urinary tract infection, nephritis, a kidney stone associated infection or a catheter-associated infection caused by Enterobacteriaceae. 
Kombinacija za uporabu prema zahtjevu 7, naznačena time što je infekcija uzrokovana sa sojem otpornim na karbapenemazu ili sojem "proširenog spektra B-laktamaze " (ESPL), kao što je New Delhi Metalo-beta-laktamaza- 1 (NDM-1) rezistentna Klebs.
Also disclosed is an isolated DNA construct, comprising a contiguous region of the human λ light chain locus from hVλ5-52 downstream to the end of hVλ1-40. 
Cc) graničnu sekvenciju humanog lokusa lakog A lanca koja se proteže od hVA5-52 do hV2A1-40 1 graničnu sekvenciju humanog lokusa lakog X lanca koja se proteže od hVA3-29 do hV23-1.
In certain embodiments, the administration of the modified angiopoietin to a subject in need thereof prevents at least one indication of neurological impairment selected from the group consisting of impaired balance or coordination, motor impairment, loss of reflexes and self-preservation, long term neurocognitive injury and impairment including memory deficits and affective disorders, lack of hygiene-related behavior, convulsion, and fitting or seizures. In certain embodiments, the modified angiopoietin is administered in combination with a second therapeutic agent or therapy. 
Pripravak za primjenu u metodi prema patentnom zahtjevu 6, naznačen time, što primjena modificiranog angiopoietina sprječava najmanje jednu indikaciju odabranu iz grupe koja se sastoji od neurološkog oštećenja i vaskularnog propuštanja, opcionalno naznačen time, što je najmanje jedna indikacija neurološkog oštećenja odabrana iz grupe koja se sastoji od narušene ravnoteže ili koordinacije, motoričkog oštećenja, gubitka refleksa 1 samoodržanja, dugoročne neurokognitivne ozljede i oštećenja, narušenog pamćenja, afektivnih poremećaja, nedostatka higijene, konvulzija i napadaja.
The closure also has a peripheral flange 23 which mates with a flange 12 of the vial 10. 
Zatvarač također ima i vanjsku prirubnicu 23 koja se sparuje s prirubnicom 12 bočice 10.
In a particularly preferred embodiment, at least two of R1-R4 is a hydroxyhydrocarbyl residue or an ester or an ether thereof. 
U naročito poželjnom ostvarenju, najmanje dva od R;-R, su hidroksihidrokarbilni ostatak ili njegov ester ili eter.
which represents an epimeric mixture of racemic compounds of formula Ia (syn) 
(lc), koji predstavlja epimernu mješavinu racemičkih spojeva sa formulom Ia (syn) HCH, CH
Figure 1 depicts fructose as it exists in several configurations in solution 
Slika 1 prikazuje fruktozu kako postoji u nekoliko konfiguracija u otopini.
A composition having a structure according to formula (IV) 
Kompozicija koja ima strukturu u skladu sa formulom (IV)
Extemporaneous viscous lubricants for use according to any one of claims 1-3 wherein the combination of CS with the HA derivative occurs just before the intra-articular or locoregional administration or directly within the treatment site following the separate administration of the two components. 
Magistarska viskozna maziva namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačena time što se CS kombinira s derivatom HA neposredno prije intraartikularne ili lokoregionalne primjene ili izravno na mjestu primjene nakon odvojene primjene dviju komponenti.
A monoclonal antibody (8F5) produced by said hybridoma of claim 5. 
Monoklonalno antitijelo (8F5) koje proizvede navedeni hibridom iz zahtjeva 5.
Particularly advantageously, the carboxylic acid is phthalic acid, citric acid or an acrylic acid/hydroxyethylacrylate copolymer, and the metal hydroxide is magnesium hydroxide. 
Proizvod iz zahtjeva 5, naznačen time da je metalna sol karboksilne kiseline magnezijev ftalat i magnezijev citrat.
an amine, optionally in the presence of an additive selecetd from an alkaline earth metal halide; 
alkoksida alkalnog metala; amina, po izboru u prisutsvu aditiva odabranog od zemnoalkalnih metala halida;
A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5 kao aktivni sastojak, uz farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
Form I of claim 10, wherein the Form I is further characterized by a peak at 7.8 degrees. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1, ili 17-22, gdje je oblik 1 dalje karakteriziran vrhom na 7.8 stupnjeva ± 0.2 stupnja.
The pharmaceutical composition of claim 6, wherein the compound of formula IIB is the compound of formula IIBb or a pharmaceutically acceptable salt, solvate, and/or ester thereof. 
[image] (IIBa) ili njegova farmaceutski prihvatljiva sol, solvat, i/ili ester. Farmaceutski sastav prema patentnom zahtjevu 5, pri čemu spoj formule IIB je spoj formule IIBb:
encoded data generated based on quantized transformation coefficients of the transformation units, wherein when the current coding unit is predicted according to the inter mode, a maximum split level of a transformation unit with respect to the current coding unit is determined based on the maximum split information for the inter mode, 
kada informacija o načinu predviđanja upućuje na to da se jedinica za kodiranje predviđa u skladu s inter načinom, određivanje maksimalne razine dijeljenja jedinice transformacije na temelju informacije o maksimalnoj podjeli za jedinicu transformacije s inter načinom;
V is lower alkylene which may be substituted with oxo (═O), 
V je C,_ alkilen koji može biti supstituiran s okso (=0).
wherein the signal includes a frequency notch band which is inserted into the signal across the signal frame and the PLP includes Layer 2, L2, signaling data carrying Program Specific Information/Service Information, PSI/SI, data. The method of claim 5, wherein the L2 signaling data includes a Network Information Table, NIT, having an identifier of a physical layer pipe (PLP_id) and an identifier of a C2 system (C2_system_id) corresponding to the transport stream, TS, and wherein a C2 delivery system descriptor includes the identifier of the PLP and the identifier of the C2 system in a TS loop of the NIT maps transport streams to PLPs in data slices of the C2 systems. 
sredstva (1803) za dobivanje NIT uključujući identifikator PLP-a (PLP_id) i identifikator sustava prijenosa (transmission_system_id) iz sloj 2, L2 informacije okvira signala, i dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru sustava prijenosa uključenog u NIT; i sredstva (1804) za dobivanje prijenosnog toka prema kojem je PLP mapiran, gdje deskriptor dostavnog sustava prijenosa uključujući identifikator PLP-a, identifikator sustava prijenosa i zaštitna intervalna polja u TS petlji NIT mapa prenose tokove do PLP-ova u podatkovnim komadima sustava prijenosa.
The method of claim 8, wherein the grace period is distinguishable from a timeslice provided to a processor on which the guest operating system executes, the guest operating system having access to shared resources of the computing environment during the timeslice, and wherein the grace period provides a period in addition to the times lice, wherein any portion of the period used by the guest operating system to perform the first function is charged against a next timeslice for the guest operating system. The method of claim 8, wherein the method further comprises: 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što se razdoblje počeka razlikuje od odsječka vremena osiguranog za procesor na kojem gostujući operativni sustav izvršava, gdje gostujući operativni sustav ima pristup dijeljenim resursima računalnog okoliša u odsječku vremena, te što razdoblje počeka osigurava dodatni period uz HR P20181992 T1 odsječak vremena, gdje se bilo koji dio perioda kojeg upotrebljava gostujući operativni sustav kako bi proveo prvu funkciju imputira na sjedeći odsječak vremena za gostujući operativni sustav.
System according to claim 6, wherein the lid and the annular sealing member are of the same material. 
Kapsula prema zahtjevu 7, naznačena time da su poklopac (9) i prstenasti brtveni element (31) od istog materijala.
In some embodiments, the process further comprises reacting the compound of Formula I, or salt thereof, with a strong acid to form compound of Formula IV: 
(b) reakciju navedenog spoja s formulom I, ili njegove soli, s koncentriranom klorovodičnom kiselinom da se dobije spoj s formulom IV ili njegova sol; i
ID. NO:74 and a light chain variable region of SEQ. 
ID. NO:74 1 varijabilno područje lakog lanca sa SEQ.
The precise molecular structure of the SDS/IL-2 microaggregates has not been determined, but they are believed to be micellar or micelle-like structures. 
Točna molekularna struktura mikroagregata SDS/IL-2 nije dosad određena, ali se za njih vjeruje da su micelarne strukture ili strukture slične micelama.
wherein n is an integer from 0 to 5, and n1 is an integer from 1 to 5; 
m? gdje n" jest cijeli broj od 0 do 10, n? jest cijeli broj od 1 do 10,